

Review of NICE Technology Appraisal Guidance No 152; drug-eluting stents (DES) for the treatment of coronary artery disease (part review of TA71)

Appendix A: Proposal comment summary table

| Respondent | Response to proposal | Details | Comment from Technology Appraisal |
|---|-----------------------------|---|--|
| Abbott Vascular Devices | Disagree | We have noted ... the review period was shortened to 12 months, rather than the previous 3 year cycle. However, conducting clinical trials by its very nature is time dependent. Abbott Vascular is in the process of collecting data in complex patient sub-sets, with the view of attaining CE mark for extended indications and when this is achieved we would welcome a re-appraisal." "...a re-appraisal at this time would not add significant weight to alter patient treatment strategy and that a deferment would be preferable." | Comment noted. |
| Boston Scientific | Disagree | "In our considered opinion, there is insufficient new evidence available to warrant a review." | Comment noted. |
| British Association for Nursing in Cardiovascular Care | Agree | | Comment noted. |
| British Cardiovascular Industry Association | Disagree | "...the view from the group is that there is no new evidence that materially affects the current guidance...We therefore request that the review is postponed to a later date." | Comment noted. |
| British Cardiovascular Society / British Cardiovascular Intervention Society | Disagree | "Although there are new data in the public domain, some of these have not reached the publication stage. Virtually all new data support the use of drug-eluting stents. However, we do not believe that there are any new trials that materially impact on the guidance issued last year and we do not see the merit in reviewing the guidance at this stage...the most appropriate response currently is to defer this review by one to two years." | Comment noted. |
| British Society for Heart Failure | No comment | "For this particular review...it is felt we may not be the appropriate society for input." | Comment noted. |
| Cordis Corporation | Disagree | "It would not seem a wise use of resource to re-open this topic again so soon. In addition to engagement with the ongoing guideline development for stable angina, acute coronary syndromes and chest pain, the NHS cardiology community is currently focussing on the implementation of primary angioplasty services and such an early review of drug-eluting stents (DES) would be a burdensome diversion | Comment noted. |

| | | | |
|--------------------------|--------------|--|--|
| | | from these important tasks. It was also clear in the last DES review that patients' preferences were to have DES available as a treatment option and to raise this question again so soon would create widespread uncertainty for them and threaten their perceptions of access to technology, choice of treatment and quality of care.... In conclusion, it would seem reasonable to allow the evidence base to refresh and take this opportunity to schedule the review onto the work programme for 2011." | |
| Department of Health | No objection | <u>Confidential information removed</u> | Comment noted. Recommendation is that review is deferred for 1 year pending publication of this information |
| Medtronic AVE | Disagree | "...a review at this point we feel would not be warranted. As stated by the Institute, new longer term data is available however on review of this data we do not feel there is sufficient evidence to contradict the guidance..." | Comment noted. |
| Royal College of Nursing | No objection | | Comment noted. |

No response received from:

| Consultees | Consultees | Commentators (no right to submit or appeal) |
|---|---|---|
| <u>Manufacturers/sponsors</u> <ul style="list-style-type: none"> • Biosensors • B. Braun Medical • Biotronik UK • Insitu Technologies • Kiwimed • Sahajanand MedicalTechnologies • Sorin Biomedica UK • Terumo Europe NV <u>Patient/carer groups</u> <ul style="list-style-type: none"> • Action Heart • Afiya Trust • Age Concern England • Black Health Agency • British Cardiac Patients Association • Cardiac Risk in the Young | <u>Professional groups</u> <ul style="list-style-type: none"> • British Association for Services to the Elderly • British Geriatrics Society • British Heart Foundation • British Society for Heart Failure • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • Society for Cardiological Science and Technology • United Kingdom Clinical Pharmacy Association • Vascular Society | <u>Comparator manufacturers</u> <ul style="list-style-type: none"> • None <u>Relevant research groups</u> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiovascular Diseases Specialist Library (CVDSL) • Central Cardiac Audit Database • Cochrane Heart Group • CORDA • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People • United Kingdom Clinical Research Network |

| Consultees | Consultees | Commentators (no right to submit or appeal) |
|--|--|---|
| <ul style="list-style-type: none"> • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Equalities National Council • Heart Care Partnership (UK) • HEART UK • Help the Aged • Muslim Council of Great Britain • Muslim Health Network • National Heart Forum • Network of Sikh Organisations UK • South Asian Health Foundation • Specialised Healthcare Alliance | <p><u>Others</u></p> <ul style="list-style-type: none"> • Barnet PCT • Derby Central PCT • Welsh Assembly Government <p>Commentators (no right to submit or appeal)</p> <p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Association of British Healthcare Industries • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • EUCOMED • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Public Health Service for Wales • NHS Purchasing and Supply Agency • NHS Alliance • NHS Confederation • NHS Quality Improvement Scotland • Scottish Medicines Consortium | <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Acute Care • National Collaborating Centre for Chronic Conditions • National Collaborating Centre for Primary Care <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None |